

T 859.04: EUA Revocation Memo Template

EUA Number	28237
Sponsor	Novavax, Inc
Product Name	Novavax COVID-19 Vaccine, Adjuvanted
Authorized Use	Active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older.
Original CBER Receipt Date of EUA Withdrawal Request (if sponsor requested withdrawal)	N/A

On February 4, 2020, as amended on March 15, 2020, pursuant to Section 564(b)(1)(C) of the Act, the Secretary of the Department of Health and Human Services (HHS) determined that there is a public health emergency, or a significant potential for a public health emergency, that affects, or that has a significant potential to affect, national security or the health and security of United States citizens living abroad, and that involves the virus that causes Coronavirus Disease 2019 (COVID-19).¹ On the basis of such determination, and pursuant to Section 564 of the Act, on March 27, 2020, the Secretary of HHS declared that circumstances exist justifying the authorization of emergency use of drugs and biological products during the COVID-19 pandemic, subject to the terms of any authorization issued under Section 564 of the Act.

On July 13, 2022, FDA issued an Emergency Use Authorization (EUA) for emergency use of Novavax COVID-19 Vaccine, Adjuvanted for the following indication: for the prevention of COVID-19 for individuals 18 years of age and older. This EUA was reissued multiple times, most recently on August 30, 2024, to among other things, authorize the use of Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) in individuals 12 years of age and older.

The authorization of a biological product for emergency use under section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. 360bbb-3) may, pursuant to section 564(g)(2) of the Act, be revised or revoked when the criteria under section 564(b)(1) of the Act no longer exist, the criteria under section 564(c) of the Act for issuance of such authorization are no longer met, or when

¹ U.S. Department of Health and Human Services, Determination of a Public Health Emergency and Declaration that Circumstances Exist Justifying Authorizations Pursuant to Section 564(b) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3. February 4, 2020. U.S. Department of Health and Human Services, *Amended Determination of a Public Health Emergency or Significant Potential for a Public Health Emergency Pursuant to Section 564(b) of the Federal Food, Drug, and Cosmetic Act*, 21 U.S.C. § 360bbb-3(b). March 15, 2023. 88 FR 16644 (March 20, 2023) (“Amended Determination”).

T 859.04: EUA Revocation Memo Template

circumstances make such revocation appropriate to protect the public health or safety (section 564(g)(2)(C) of the Act).

FDA has determined that circumstances make such revocation appropriate to protect the public health or safety (section 564(g)(2)(C) of the Act). We are not aware of any plans Novavax, Inc. has to distribute vaccine under the EUA. There are approved COVID-19 vaccines for use in certain individuals in the age group that is the target of the EUA, including an approved vaccine for which Novavax, Inc. is the license holder. Specifically, there are approved COVID-19 vaccines for use in individuals who are 65 years of age and older, or 12 through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19. In addition, the circumstances of COVID-19 are not what they previously were. The risk of severe outcomes from COVID-19 has decreased dramatically over the last four years.² Hospitalizations from COVID-19 have declined between 2021 and 2025.³ The infection fatality rate is estimated to have decreased approximately 10-fold with the emergence of newer variants of SARS-CoV-2⁴. Furthermore, naturally acquired immunity from SARS-CoV-2 infection(s) that prevents severe COVID-19 appears robust.⁵ While safety concerns are not the basis for our decision to revoke the EUA, due to all of these circumstances, I have determined that circumstances exist that make it appropriate to revoke EUA 28237 and doing so is appropriate to protect the public health or safety.

Accordingly, pursuant to section 564(g)(2) of the FD&C Act, I recommend revoking EUA 28237 for emergency use of the Novavax COVID-19 Vaccine, Adjuvanted, effective the date the FDA revocation letter is signed. There are no open amendments associated with this EUA at the time of this revocation.

FDA provided notice of the agency's intent to revoke the EUA on July 11, 2025, and this decision is consistent with the notice we provided. Notice of this revocation will also be published in the Federal Register, pursuant to section 564(h)(1) of the Act.

² Riedmann U, Chalupka A, Richter L, Sprenger M, Rauch W, Krause R, Willeit P, Schennach H, Benka B, Werber D, Høeg TB, Ioannidis JP, Pilz S. COVID-19 case fatality rate and infection fatality rate from 2020 to 2023: Nationwide analysis in Austria. *J Infect Public Health*. 2025 Apr;18(4):102698.

³ Thornburg, N. 2024-2025 Update on Current Epidemiology of COVID-19 and SARS-CoV-2 Genomics. CDC May 2025 <https://www.fda.gov/media/186593/download>.

⁴ Riedmann U, Chalupka A, Richter L, Sprenger M, Rauch W, Krause R, Willeit P, Schennach H, Benka B, Werber D, Høeg TB, Ioannidis JP, Pilz S. COVID-19 case fatality rate and infection fatality rate from 2020 to 2023: Nationwide analysis in Austria. *J Infect Public Health*. 2025 Apr;18(4):102698.

⁵ Prasad, V., Makaray, M.A., An evidence-based approach to COVID-19 vaccination. *NEJM*. 2025 June 392(24):2484.

T 859.04: EUA Revocation Memo Template

Signature: _____
Center Director
Vinayak Prasad, M.D., M.P.H.